Aurobindo gets nod for Cefuroxime Axetil Tablets
Mumbai, April 3 (UNI) Aurobindo Pharma today announced that it has received approval for Cefuroxime Axetil Tablets USP, 125 mg (base), 250 mg (base), 500 mg (base) from US FDA.
With this Oral Cephalosporin approval, the company's product basket for the US market has increased to 13 (final approvals), it informed BSE here today, accordingly.
Apart from this, the company has 10 tentative approvals for the US market.
The size of generics business of Cefuroxime Axetil 125/ 250/ 500 mg is around USD 50 million.
Cefuroxime Axetil tablets are indicated for the treatment of patients with infections caused by susceptible strains of designated organisms in the following diseases: Pharyngitis and Tonsillitis, Lower Respiratory Tract Infections, Urinary Tract Infections and Skin Structure Infections.
Cefuroxime Axetil Tablets USP, 125 mg (base), 250 mg (base), 500 mg (base) is the generic version of Glaxo Wellcomes Ceftin.
UNI SN MJ AG1551